IVVD
Invivyd, Inc.
Biotechnology · Healthcare · United States
0.58
close · 2026-10-30
value
9
cheaper than peers9
quality
44
stronger fundamentals44
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.95× | 86 |
| price to sales | 2.94× | 82 |
| cash flow yield, latest year | -34.0% | 23 |
| earnings yield, latest year | -51.6% | 21 |
| cash flow yield, 3 years ago | -129.3% | 10 |
| cash flow yield, 2 years ago | -101.4% | 9 |
| cash flow yield, 1 year ago | -99.5% | 8 |
| earnings yield, 2 years ago | -311.2% | 6 |
| earnings yield, 1 year ago | -245.8% | 6 |
| earnings yield, 3 years ago | -383.4% | 6 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 4.6% | 73 |
| revenue growth | 21.2% | 52 |
| operating margin | -320.8% | 40 |
| return on equity | -95.9% | 26 |
4 of 4 measures available
Facts
| market cap | $171M |
| free cash flow | -$70.0M |
| employees | 122 |
| first trade | 2021-08-06 |
| next earnings | not reported |
| fundamentals updated | 2026-08-21 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.30 | -1.43 | -1.81 | -2.23 | not reported |
| free cash flow | -$58.3M | -$170.6M | -$173.8M | -$221.7M | not reported |
| net income | -$52.5M | -$169.9M | -$198.6M | -$241.3M | not reported |
| revenue | $53.4M | $25.4M | $0 | $0 | not reported |
| unusual items | not reported | $0 | -$5.0M | -$21.8M | -$7.5M |